Skip to main content
. Author manuscript; available in PMC: 2016 Apr 1.
Published in final edited form as: Am J Hematol. 2015 Feb 25;90(4):327–333. doi: 10.1002/ajh.23946

Table 5.

Non-compartmental parameter estimates for lenalidomide and flavopiridol by treatment category, where C1D1 represents flavopiridol alone, C2D2 is lenalidomide alone, and C2D3 is combined lenalidomide and flavopiridol. Values represent the average of individual parameter estimates followed by standard deviations in parenthesis.

Treatment N AUCINF_pred
(hr*µmol/L)		 Cmax
(µmol/L)		 Cl_F_pred
(L/hr)		 Vz_F_pred
(L)		 HL_Lambda_z
(hr)		 Tmax
(hr)
Flavopiridol C1D1 36 19.23 (11.45) 2.53 (1.46) 12.66 (7.20) 270.9 (244.9) 15.78 (11.89) 1.34 (1.63)
C2D3 32 20.51 (11.91) 2.57 (1.30) 11.71 (7.16) 264.9 (264.4) 16.28 (12.18) 1.31 (1.37)
Lenalidomide C2D2 31 2.93 (2.04) 0.65 (0.46) 14.43 (9.05) 76.0 (48.5) 3.71 (1.23) 1.33 (0.77)
C2D3 32 2.53 (1.90) 0.45 (0.37) 18.43 (13.97) 85.7 (64.5) 3.36 (1.08) 3.73 (6.69)